[HTML][HTML] TP53 co-mutations in advanced EGFR-mutated non–small cell lung cancer: Prognosis and therapeutic strategy for cancer therapy
S Liu, J Yu, H Zhang, J Liu - Frontiers in oncology, 2022 - frontiersin.org
Lung cancer is the leading cause of cancer-related deaths worldwide. As the most prevalent
molecular mutation subtypes in non-small cell lung cancer (NSCLC), EGFR-TKIs are …
molecular mutation subtypes in non-small cell lung cancer (NSCLC), EGFR-TKIs are …
Prognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC)
C Labbé, M Cabanero, GJ Korpanty, P Tomasini… - Lung Cancer, 2017 - Elsevier
Introduction TP53 mutations are common in non-small cell lung cancer (NSCLC) and have
been reported as prognostic of poor outcome. The impact of TP53 co-mutations in epidermal …
been reported as prognostic of poor outcome. The impact of TP53 co-mutations in epidermal …
[HTML][HTML] Meta-analysis of the prognostic impact of TP53 co-mutations in EGFR-mutant advanced non-small-cell lung cancer treated with tyrosine kinase inhibitors
MG Ferrara, L Belluomini, A Smimmo, M Sposito… - Critical Reviews in …, 2023 - Elsevier
Purpose To assess the prognostic impact of TP53 mutations in EGFR-mutant advanced
NSCLC patients treated with TKIs. Methods Studies exploring the clinical outcomes of EGFR …
NSCLC patients treated with TKIs. Methods Studies exploring the clinical outcomes of EGFR …
[HTML][HTML] Prognostic value of TP53 concurrent mutations for EGFR-TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis
K Qin, H Hou, Y Liang, X Zhang - BMC cancer, 2020 - Springer
Background The prognostic significance of TP53 concurrent mutations in patients with
epidermal growth factor receptor (EGFR)-or anaplastic lymphoma kinase (ALK)-mutated …
epidermal growth factor receptor (EGFR)-or anaplastic lymphoma kinase (ALK)-mutated …
[HTML][HTML] Efficacy of EGFR-TKI plus chemotherapy or monotherapy as first-line treatment for advanced EGFR-mutant lung adenocarcinoma patients with co-mutations
Z Yang, Y Chen, Y Wang, S Wang, M Hu… - Frontiers in …, 2021 - frontiersin.org
Background Co-mutations was associated with poor response to EGFR-TKIs. First-
generation EGFR-TKIs combined with chemotherapy was reported to be more effective than …
generation EGFR-TKIs combined with chemotherapy was reported to be more effective than …
Predictive and Prognostic Potential of TP53 in Patients with Advanced Non–Small-Cell Lung Cancer Treated with EGFR-TKI: Analysis of a Phase III Randomized …
XM Li, WF Li, JT Lin, HH Yan, HY Tu, HJ Chen… - Clinical lung cancer, 2021 - Elsevier
Background Mutations in TP53 are commonly found in patients with epidermal growth factor
receptor (EGFR) mutant advanced non–small-cell lung cancer (NSCLC). In this study, we …
receptor (EGFR) mutant advanced non–small-cell lung cancer (NSCLC). In this study, we …
[HTML][HTML] Optimal therapy for concomitant EGFR and TP53 mutated non-small cell lung cancer: a real-world study
H Sun, P Ren, Y Chen, L Lan, Z Yan, Y Yang, B Wang… - BMC cancer, 2023 - Springer
Background Non-small cell cancer (NSCLC) patients with concomitant epidermal growth
factor receptor (EGFR) and TP53 mutations have a poor prognosis with the treatment of …
factor receptor (EGFR) and TP53 mutations have a poor prognosis with the treatment of …
[HTML][HTML] Concomitant TP53 Mutation Confers Worse Prognosis in EGFR-Mutated Non-Small Cell Lung Cancer Patients Treated with TKIs
M Canale, E Petracci, A Delmonte, G Bronte… - Journal of clinical …, 2020 - mdpi.com
Background: Non-small cell lung cancer (NSCLC) is the primary cause of cancer-related
deaths worldwide. Epidermal Growth Factor Receptor (EGFR)-mutated patients usually …
deaths worldwide. Epidermal Growth Factor Receptor (EGFR)-mutated patients usually …
Impact of TP53 Mutations on Outcome in EGFR-Mutated Patients Treated with First-Line Tyrosine Kinase Inhibitors
M Canale, E Petracci, A Delmonte, E Chiadini… - Clinical Cancer …, 2017 - AACR
Purpose: To analyze the impact of TP53 mutations on response to first-line tyrosine kinase
inhibitors (TKI) in patients with EGFR-mutated non–small cell lung cancer (NSCLC) …
inhibitors (TKI) in patients with EGFR-mutated non–small cell lung cancer (NSCLC) …
[HTML][HTML] TP53 Co-Mutation Status Association with Clinical Outcomes in Patients with EGFR-Mutant Non-Small Cell Lung Cancer
X Le, C Molife, MS Leusch, MT Rizzo, PM Peterson… - Cancers, 2022 - mdpi.com
Simple Summary There is conflicting evidence on the impact of TP53 co-mutations on
survival in patients with EGFR-mutated advanced non-small cell lung cancer (aNSCLC) …
survival in patients with EGFR-mutated advanced non-small cell lung cancer (aNSCLC) …